Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014–2015

• Published in: Antiviral research Vol. 132; pp. 178 - 185
• Main Authors: Hurt, Aeron C., Besselaar, Terry G., Daniels, Rod S., Ermetal, Burcu, Fry, Alicia, Gubareva, Larisa, Huang, Weijuan, Lackenby, Angie, Lee, Raphael T.C., Lo, Janice, Maurer-Stroh, Sebastian, Nguyen, Ha T., Pereyaslov, Dmitriy, Rebelo-de-Andrade, Helena, Siqueira, Marilda M., Takashita, Emi, Tashiro, Masato, Tilmanis, Danielle, Wang, Dayan, Zhang, Wenqing, Meijer, Adam
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.08.2016; Elsevier
• Subjects: Antiviral Agents - pharmacology; Antiviral Agents - therapeutic use; Antiviral resistance; Databases, Factual; Dose-Response Relationship, Drug; Drug Resistance, Viral; Global analysis; Global Health; History, 21st Century; Humans; Influenza A virus - classification; Influenza A virus - drug effects; Influenza A virus - enzymology; Influenza A virus - genetics; Influenza virus; Influenza, Human - drug therapy; Influenza, Human - epidemiology; Influenza, Human - history; Influenza, Human - virology; Microbial Sensitivity Tests; Mutation; Neuraminidase - antagonists & inhibitors; Neuraminidase - genetics; Neuraminidase inhibitors; Oseltamivir; Population Surveillance; Reduced susceptibility; Viral Proteins - antagonists & inhibitors; Viral Proteins - genetics; World Health Organization; Oseltamivir; Reduced susceptibility; Influenza virus; Neuraminidase inhibitors; Antiviral resistance; Global analysis
• ISSN: 0166-3542; 1872-9096
• DOI: 10.1016/j.antiviral.2016.06.001

The World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza (WHO CCs) tested 13,312 viruses collected by WHO recognized National Influenza Centres between May 2014 and May 2015 to determine 50% inhibitory concentration (IC50) data for neuraminidase inhibitors (NAIs) oseltamivir, zanamivir, peramivir and laninamivir. Ninety-four per cent of the viruses tested by the WHO CCs were from three WHO regions: Western Pacific, the Americas and Europe. Approximately 0.5% (n = 68) of viruses showed either highly reduced inhibition (HRI) or reduced inhibition (RI) (n = 56) against at least one of the four NAIs. Of the twelve viruses with HRI, six were A(H1N1)pdm09 viruses, three were A(H3N2) viruses and three were B/Yamagata-lineage viruses. The overall frequency of viruses with RI or HRI by the NAIs was lower than that observed in 2013–14 (1.9%), but similar to the 2012–13 period (0.6%). Based on the current analysis, the NAIs remain an appropriate choice for the treatment and prophylaxis of influenza virus infections. •A total of 13,312 influenza viruses were collected worldwide, May 2014–May 2015.•Approximately 0.5% showed reduced inhibition by at least one NA inhibitor.•The frequency of viruses with reduced inhibition was lower than in 2013–14 (1.9%).•NA inhibitors remain an appropriate choice for influenza treatment and prophylaxis.•Global surveillance of influenza antiviral susceptibility should be continued.